Pfizer Sees Increased Cardiovascular Risk With Bextra After Bypass Surgery

Two studies on short-term use of a parecoxib/Bextra treatment regimen following coronary artery bypass graft surgery showed an increased risk of cardiovascular events. Pfizer discusses the surgery study results as part of a "Dear Health Care Professional" letter about skin reactions associated with Bextra.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet